478 related articles for article (PubMed ID: 31601022)
1. Butyrylcholinesterase Protein Ends in the Pathogenesis of Alzheimer's Disease-Could
Jasiecki J; Wasąg B
Biomolecules; 2019 Oct; 9(10):. PubMed ID: 31601022
[No Abstract] [Full Text] [Related]
2. Synergy between the alteration in the N-terminal region of butyrylcholinesterase K variant and apolipoprotein E4 in late-onset Alzheimer's disease.
Jasiecki J; Limon-Sztencel A; Żuk M; Chmara M; Cysewski D; Limon J; Wasąg B
Sci Rep; 2019 Mar; 9(1):5223. PubMed ID: 30914707
[TBL] [Abstract][Full Text] [Related]
3. Variability of AChE, BChE, and ChAT genes in the late-onset form of Alzheimer's disease and relationships with response to treatment with Donepezil and Rivastigmine.
Scacchi R; Gambina G; Moretto G; Corbo RM
Am J Med Genet B Neuropsychiatr Genet; 2009 Jun; 150B(4):502-7. PubMed ID: 18780301
[TBL] [Abstract][Full Text] [Related]
4. A Systematic Review on Donepezil-based Derivatives as Potential Cholinesterase Inhibitors for Alzheimer's Disease.
Korabecny J; Spilovska K; Mezeiova E; Benek O; Juza R; Kaping D; Soukup O
Curr Med Chem; 2019; 26(30):5625-5648. PubMed ID: 29768996
[TBL] [Abstract][Full Text] [Related]
5. Haplotypes of butyrylcholinesterase K-variant and their influence on the enzyme activity.
Jasiecki J; Żuk M; Krawczyńska N; Jońca J; Szczoczarz A; Lewandowski K; Waleron K; Wasąg B
Chem Biol Interact; 2019 Jul; 307():154-157. PubMed ID: 31071335
[TBL] [Abstract][Full Text] [Related]
6. BCHE and CYP2D6 genetic variation in Alzheimer's disease patients treated with cholinesterase inhibitors.
Chianella C; Gragnaniello D; Maisano Delser P; Visentini MF; Sette E; Tola MR; Barbujani G; Fuselli S
Eur J Clin Pharmacol; 2011 Nov; 67(11):1147-57. PubMed ID: 21630031
[TBL] [Abstract][Full Text] [Related]
7. Butyrylcholinesterase K and Apolipoprotein E-ɛ4 Reduce the Age of Onset of Alzheimer's Disease, Accelerate Cognitive Decline, and Modulate Donepezil Response in Mild Cognitively Impaired Subjects.
De Beaumont L; Pelleieux S; Lamarre-Théroux L; Dea D; Poirier J;
J Alzheimers Dis; 2016 Oct; 54(3):913-922. PubMed ID: 27567841
[TBL] [Abstract][Full Text] [Related]
8. Butyrylcholinesterase: K variant, plasma activity, molecular forms and rivastigmine treatment in Alzheimer's disease in a Southern Brazilian population.
Bono GF; Simão-Silva DP; Batistela MS; Josviak ND; Dias PF; Nascimento GA; Souza RL; Piovezan MR; Souza RK; Furtado-Alle L
Neurochem Int; 2015 Feb; 81():57-62. PubMed ID: 25624079
[TBL] [Abstract][Full Text] [Related]
9. Deleterious Effect of Butyrylcholinesterase K-Variant in Donepezil Treatment of Mild Cognitive Impairment.
Sokolow S; Li X; Chen L; Taylor KD; Rotter JI; Rissman RA; Aisen PS; Apostolova LG
J Alzheimers Dis; 2017; 56(1):229-237. PubMed ID: 27911294
[TBL] [Abstract][Full Text] [Related]
10. Effect of rivastigmine or memantine add-on therapy is affected by butyrylcholinesterase genotype in patients with probable Alzheimer's disease.
Han HJ; Kwon JC; Kim JE; Kim SG; Park JM; Park KW; Park KC; Park KH; Moon SY; Seo SW; Choi SH; Cho SJ
Eur Neurol; 2015; 73(1-2):23-8. PubMed ID: 25376930
[TBL] [Abstract][Full Text] [Related]
11. Tailored Modeling of Rivastigmine Derivatives as Dual Acetylcholinesterase and Butyrylcholinesterase Inhibitors for Alzheimer's Disease Treatment.
Adeowo FY; Oyetunji TP; Ejalonibu MA; Ndagi U; Kumalo HM; Lawal MM
Chem Biodivers; 2021 Nov; 18(11):e2100361. PubMed ID: 34547176
[TBL] [Abstract][Full Text] [Related]
12. Effect of butyrylcholinesterase genotype on the response to rivastigmine or donepezil in younger patients with Alzheimer's disease.
Blesa R; Bullock R; He Y; Bergman H; Gambina G; Meyer J; Rapatz G; Nagel J; Lane R
Pharmacogenet Genomics; 2006 Nov; 16(11):771-4. PubMed ID: 17047484
[TBL] [Abstract][Full Text] [Related]
13. Rivastigmine: the advantages of dual inhibition of acetylcholinesterase and butyrylcholinesterase and its role in subcortical vascular dementia and Parkinson's disease dementia.
Kandiah N; Pai MC; Senanarong V; Looi I; Ampil E; Park KW; Karanam AK; Christopher S
Clin Interv Aging; 2017; 12():697-707. PubMed ID: 28458525
[TBL] [Abstract][Full Text] [Related]
14. In Silico Analysis of Green Tea Polyphenols as Inhibitors of AChE and BChE Enzymes in Alzheimer's Disease Treatment.
Ali B; Jamal QM; Shams S; Al-Wabel NA; Siddiqui MU; Alzohairy MA; Al Karaawi MA; Kesari KK; Mushtaq G; Kamal MA
CNS Neurol Disord Drug Targets; 2016; 15(5):624-8. PubMed ID: 26996169
[TBL] [Abstract][Full Text] [Related]
15. Sensitivity of butyrylcholinesterase knockout mice to (--)-huperzine A and donepezil suggests humans with butyrylcholinesterase deficiency may not tolerate these Alzheimer's disease drugs and indicates butyrylcholinesterase function in neurotransmission.
Duysen EG; Li B; Darvesh S; Lockridge O
Toxicology; 2007 Apr; 233(1-3):60-9. PubMed ID: 17194517
[TBL] [Abstract][Full Text] [Related]
16. Association of Butyrylcholinesterase-K Allele and Apolipoprotein E ɛ4 Allele with Cognitive Decline in Dementia with Lewy Bodies and Alzheimer's Disease.
Vijayaraghavan S; Darreh-Shori T; Rongve A; Berge G; Sando SB; White LR; Auestad BH; Witoelar A; Andreassen OA; Ulstein ID; Aarsland D
J Alzheimers Dis; 2016; 50(2):567-76. PubMed ID: 26757188
[TBL] [Abstract][Full Text] [Related]
17. Progression from mild cognitive impairment to Alzheimer's disease: effects of sex, butyrylcholinesterase genotype, and rivastigmine treatment.
Ferris S; Nordberg A; Soininen H; Darreh-Shori T; Lane R
Pharmacogenet Genomics; 2009 Aug; 19(8):635-46. PubMed ID: 19617863
[TBL] [Abstract][Full Text] [Related]
18. Cholinesterase Inhibitors for Alzheimer's Disease: Multitargeting Strategy Based on Anti-Alzheimer's Drugs Repositioning.
Kabir MT; Uddin MS; Begum MM; Thangapandiyan S; Rahman MS; Aleya L; Mathew B; Ahmed M; Barreto GE; Ashraf GM
Curr Pharm Des; 2019; 25(33):3519-3535. PubMed ID: 31593530
[TBL] [Abstract][Full Text] [Related]
19. Discovery of Novel Pyrazolopyrimidinone Derivatives as Phosphodiesterase 9A Inhibitors Capable of Inhibiting Butyrylcholinesterase for Treatment of Alzheimer's Disease.
Yu YF; Huang YD; Zhang C; Wu XN; Zhou Q; Wu D; Wu Y; Luo HB
ACS Chem Neurosci; 2017 Nov; 8(11):2522-2534. PubMed ID: 28783948
[TBL] [Abstract][Full Text] [Related]
20. Rivastigmine-Bambuterol Hybrids as Selective Butyrylcholinesterase Inhibitors.
Wu J; Tan Z; Pistolozzi M; Tan W
Molecules; 2023 Dec; 29(1):. PubMed ID: 38202655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]